IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2868
-0.0038 (-1.31%)
Mar 12, 2026, 3:01 PM EDT - Market open

IGC Pharma Cash Flow Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Net Income
-6.45-7.12-13-11.51-15.02-8.81
Depreciation & Amortization
0.570.620.640.660.650.48
Stock-Based Compensation
2.021.641.772.842.20.66
Other Adjustments
-0.970.143.50.172.170.17
Change in Receivables
-0.01-0.01-0.030.010.05-0.04
Changes in Inventories
0.170.181.010.91.93-1.23
Changes in Accounts Payable
-0.140.110.24-0.450.5-0.29
Changes in Accrued Expenses
-1.17-0.20.2-0.09-0.130.37
Changes in Unearned Revenue
0-----
Changes in Other Operating Activities
0.42-0.150.470.430.18-2.11
Operating Cash Flow
-5.54-4.8-5.2-7.05-7.46-10.8
Capital Expenditures
-0.08-0.11-0.14-0.31-0.24-1.47
Sale of Property, Plant & Equipment
0.720.040.040.540.03-
Purchases of Intangible Assets
-0.64-0.37-0.38-0.31-0.54-0.12
Purchases of Investments
-0.01----4.93
Proceeds from Sale of Investments
--0.15-0.15-0.05
Investing Cash Flow
-0.04-0.44-0.32-0.24-0.743.39
Long-Term Debt Issued
-----0.53
Long-Term Debt Repaid
-0-0-0-0-0-
Net Long-Term Debt Issued (Repaid)
-0-0-0-0-00.53
Issuance of Common Stock
5.124.453.530.14.1514.16
Net Common Stock Issued (Repurchased)
5.124.453.530.14.1514.16
Financing Cash Flow
5.114.453.520.14.1414.69
Effect of Exchange Rate Changes on Cash and Cash Equivalents
0.03-0.01-0.01-0.08-0.030.02
Net Cash Flow
-0.34-0.79-2-7.26-4.097.29
Free Cash Flow
-5.63-4.91-5.34-7.36-7.7-12.27
FCF Margin
-508.68%-386.07%-396.80%-807.57%-1939.04%-1366.37%
Free Cash Flow Per Share
-0.07-0.06-0.09-0.14-0.15-0.29
Levered Free Cash Flow
-6.69-6.68-10.59-10.37-12.12-12.53
Unlevered Free Cash Flow
-8.33-7-7.38-10.44-12.53-12.97
Updated Nov 14, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q